

# Statistical methods for ranking differentially expressed genes

## Per Broberg

Address: Molecular Sciences, AstraZeneca Research and Development Lund, S-221 87 Lund, Sweden.

Correspondence: Per Broberg. E-mail: per.broberg@astrazeneca.com.

Published: 29 May 2003

*Genome Biology* 2003, **4**:R41

The electronic version of this article is the complete one and can be found online at <http://genomebiology.com/2003/4/6/R41>

Received: 9 December 2002

Revised: 25 March 2003

Accepted: 7 May 2003

A previous version of this manuscript was made available before peer review at <http://genomebiology.com/2002/3/9/preprint/0007>

© 2003 Broberg; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.

### Abstract

In the analysis of microarray data the identification of differential expression is paramount. Here I outline a method for finding an optimal test statistic with which to rank genes with respect to differential expression. Tests of the method show that it allows generation of top gene lists that give few false positives and few false negatives. Estimation of the false-negative as well as the false-positive rate lies at the heart of the method.

### Background

Microarray technology has revolutionized modern biological research by permitting the simultaneous study of genes comprising a large part of the genome. The blessings stemming from this are accompanied by the curse of high dimensionality of the data output. The main objective of this article is to explore one method for ranking genes in order of likelihood of being differentially expressed. Top gene lists, that give few false positives and few false negatives, are the output. As the interest is mainly in ranking for the purpose of generating top gene lists, issues such as calculation of *p*-values and correction for multiple tests are of secondary importance.


Microarrays have an important role in finding novel drug targets; the thinking that guides the design and interpretation of such experiments has been expressed by Lonnstedt and Speed [1]: "The number of genes selected would depend on the size, aim, background and follow-up plans of the experiment." Often, interest is restricted to so-called 'druggable' target classes, thus thinning out the set of eligible genes considerably. It is generally sensible to focus attention first on druggable targets with smaller *p*-values (where the *p*-value is the probability of obtaining at least the same degree of differential expression by pure chance) before proceeding to ones with larger *p*-values. In general, *p*-values have the greatest

impact on decisions regarding target selection by providing a preliminary ranking of the genes. This is not to say that multiplicity should never be taken into account, or that the method presented here replaces correction for multiplicity. On the contrary, the approach provides a basis for such calculations (see Additional data files).

The approach presented here could be applied to different types of test statistics, but one particular type of recently proposed statistic will be used. In Tusher [2] a methodology based on a modified *t*-statistic is described:

$$d = \frac{\text{diff}}{S_0 + S} \quad (1)$$

where *diff* is an effect estimate, for example, a group mean difference, *S* is a standard error, and *S*<sub>0</sub> is a regularizing constant. This formulation is quite general and includes, for example, the estimation of a contrast in an ANOVA. Setting *S*<sub>0</sub> = 0 will yield a *t*-statistic. The constant, called the fudge constant, is found by removing the trend in *d* as a function of *S* in moving windows across the data. The technical details are outlined in [3]. The statistic calculated in this way will be referred to as SAM. The basic idea with *d* is to eliminate some false positives with low values of *S*, see Figure 1.

**Figure 1**

The effect of  $S_0$ . With real microarray data the absolute value of the  $t$ -statistic often shows erratic behavior for small values of the standard error  $S$ , with an increased risk of false positives. By choosing the constant  $S_0$  in equation (1) wisely one can alleviate this problem. In the right panel we see that the statistic  $d$  in equation (1) downplays the importance of some of the genes with low standard error, compared to the  $t$ -statistic (left panel). Data from Golub [16] were used, and  $S_0$  was chosen as the 5% percentile of  $S$  values (see also Discussion).


It is more relevant to optimize with respect to false-positive and false-negative rates. This is the basic idea behind the new approach. The idea is to jointly minimize the number of genes that are falsely declared positive and the number of genes falsely declared negative by optimizing over a range of values of the significance level  $\alpha$  and the fudge constant  $S_0$ . How well this is achieved can be judged by a receiver operating characteristics (ROC) curve, which displays the number of false positives against the number of false negatives expressed as proportions of the total number of genes.

An alternative to the statistic (1) is  $d = \text{diff} / \sqrt{(S_0^2 + S^2)}$ , or  $d = \text{diff} / \sqrt{(wS_0^2 + (1-w)S^2)}$  for some weight  $w$ , which is basically the statistic proposed in Baldi [4]. Its performance appears to be very similar to that of (1) (data not shown). A software implementation in R code within the package SAG [5,6] is available from [7] via the function *samroc*.

## Results

### The criterion

A comparison of methods in terms of their ROC curves is presented in Lonnstedt [1]. A method whose ROC curve lies below another one (has smaller ordinate for given abscissa) is preferred (Figure 2). A method which has a better ROC curve, in this sense, will produce top lists with more differentially

**Figure 2**

ROC curve. This graph displays the number of false negatives (differentially expressed genes (DEGs) not included) versus the number of false positives (non-DEGs included) found on top lists of increasing sizes, expressed as proportions of the total number of genes. The distance  $C$  gives an optimal value of equation (2). A method whose ROC curve lies below that of another method is preferable, as it will give more DEGs and fewer non-DEGs on any top list of any size, as explained in Additional data. Hence method 1 is preferable to method 2.

expressed genes (DEGs), fewer non-DEGs, and, consequently, will leave out fewer DEGs. Furthermore, such a method will give higher average ranks to the DEGs, if the ranking is such that high rank means more evidence of differential expression. Superiority in terms of average ranks is a weaker assertion than superiority in terms of ROC curves (see Additional data files for a proof). If it is desirable to compare methods with respect to their ROC curves, then the estimation procedures should find parameter estimates that optimize the ROC curve. This section suggests a goodness criterion based on the ROC curve.

False discovery rate (*FDR*) may be defined as the proportion of false positives among the significant genes, see [2]. False-positive rate (*FP*) may be defined as the number of false positives among the significant genes divided by the total number of genes. Similarly, we define the false-negative rate (*FN*) as the number of false negatives among the nonsignificant genes divided by the total number of genes, the true-positive rate (*TP*) as the number of true positives divided by the total number of genes, and, the true-negative rate (*TN*) as the number of true negatives divided by the total number of genes.

In Table 1 relations involving these entities are displayed. For instance, the proportion of unchanged genes (non-DEGs),  $p_0$ , equals the sum of the proportion of true negative and the

**Table 1**

**The unknown distribution of true and false positives and negatives**

	Negative	Positive
True	<i>TN</i>	<i>TP</i>
False	<i>FN</i>	<i>FP</i>
$\Sigma$	$1 - p(\alpha)$	$p(\alpha)$

The proportion of incorrectly called genes equals  $FN + FP$ , and the proportion called significant equals  $p(\alpha) = TP + FP$ .

proportion of false positive:  $p_0 = TN + FP$ , and the proportion of significant genes at a certain significance level  $\alpha$  equals the sum of the true positives and the false positives:  $p(\alpha) = TP + FP$ . It is intuitive that the criterion to be minimized should be an increasing function of  $FP$  and  $FN$ . Any top list produced should have many DEGs and few non-DEGs.

Assume that we can, for every combination of values of the significance level  $\alpha$  and the fudge constant  $S_0$ , calculate ( $FP$ ,  $FN$ ). The goodness criterion is then formulated in terms of the distance of the points ( $FP$ ,  $FN$ ) to the origin (which point corresponds to no false positives and no false negatives, see Figure 2), which in mathematical symbols may be put as

$$C = \sqrt{FP^2 + FN^2} \quad (2)$$

The optimal value of ( $\alpha$ ,  $S_0$ ) will be the one that minimizes (2). It is for practical reasons not possible to do this minimization over every combination, so the suggestion is to estimate the criterion over a lattice of ( $\alpha$ ,  $S_0$ ) values and pick the best combination.

If one has an assessment regarding the relative importance of  $FP$  and  $FN$ , that may be reflected in a version of the criterion (2) that incorporates a weight  $\lambda$  that reflects the relative importance of  $FP$  compared to  $FN$ :  $C_\lambda = \sqrt{(\lambda^2 FP^2 + FN^2)}$ . The choice  $\lambda = (1 - p_0)/p_0$  corresponds to another type of ROC curve, which displays the proportion of true ( $TP/(1 - p_0)$ ) against the proportion of false ( $FP/p_0$ ) (see Additional data files). Other goodness criteria are possible, such as the sum of  $FP$  and  $FN$  or the area under the curve in Figure 2. For more details and other approaches see, for example [8,9].

**Calculating p-values**

Using the permutation method to simulate the null distribution (no change) we can obtain a  $p$ -value for a two-sided test, as detailed below. Loosely speaking, in each loop of the simulation algorithm the group labels are randomly rearranged, so that random groups are formed, the test statistic is calculated for this arrangement and the value is compared to the observed one. How extreme the observed test statistic is will be

judged by counting the number of times that more extreme values are obtained from the null distribution.

The data matrix  $X$  has genes in rows and arrays in columns. Consider the vector of group labels fixed. The permutation method consists of repeatedly permuting the columns (equivalent to rearranging group labels), thus obtaining the matrix  $X^*$ , and calculating the test statistic for each gene and each permutation. Let  $d(j)^{*k}$  be the value of the statistic of the  $j$ th gene in the  $k$ th permutation of columns. Then the  $p$ -value for gene  $i$  equals

$$P_i = \frac{\#\{d(j)^{*k} : |d(j)^{*k}| \geq |d(i)|\}}{B \times M} \quad (3)$$

where  $M$  is the number of genes,  $d(i)$  the observed statistic for gene  $i$ ,  $B$  the number of permutations and '#' denotes the cardinality of the set [2,10,11]. In words, this gives the relative frequency of randomly generated test statistics with an absolute value that exceeds the observed value of gene  $i$ . The formula (3) combines the permutation method in [2] and the  $p$ -value calculation in [10]. These  $p$ -values are such that a more extreme value of the test statistic will yield a lower  $p$ -value.

Given the significance level  $\alpha$  ( $p$ -values less than  $\alpha$  are considered significant), the proportion of the genes considered differentially expressed is

$$p(\mathbf{a}) = \frac{\#\{i : P_i \leq \mathbf{a}\}}{M}, \quad (4)$$

which is the relative frequency of genes with a  $p$ -value less than  $\alpha$ .

The current version of *samroc* uses the estimate

$$\check{p}_0 = \frac{\#\{i : q_{25} \leq d(i) \leq q_{75}\}}{M/2} \quad (5)$$


where  $q_X$  is the  $X\%$  percentile of the  $d^*$  (compare [3]). This estimate makes use of the fact that the genes whose test statistics fall in the quartile range will be predominantly the unchanged ones. More material on this matter is in the Additional data files.

**Estimating FP**

Going via results for the *FDR* in Storey [12] (see also [13,14]) it is possible to derive the estimate

$$\check{F}P = \check{p}_0 \mathbf{a}$$

which is the proportion of unchanged genes multiplied by the probability that such a gene produces a significant result. For a derivation see the Additional data files.



**Figure 3**

Estimates of the criterion. The true and the estimated value of the goodness criterion  $\sqrt{(FP^2 + FN^2)}$ . Using data from the simulated cDNA distributions, the true *FP* and *FN* were calculated and then estimated. Finally, the goodness criterion was calculated and displayed in a scatter plot, showing a good correspondence between estimate and estimand.

### Estimating *FN*

From Table 1 one obtains, as outlined in the Additional data files,

$$FN = 1 - p_o(1 - \alpha) - p(\alpha) \quad (6)$$

To get an intuitive feel for this equality, just note that the second term is the proportion unchanged multiplied by the probability of such genes not being significant, which estimates *TN*, and that the third term corresponds to the positive (*TP* + *FP*). Subtracting the proportion of these two categories from the whole will leave us with the *FN*.

### Estimating the criterion

The entities we need for the optimisation are given by the estimates

$$\check{FN} = 1 - \check{p}_o(1 - \check{\alpha}) - p(\check{\mathbf{a}})$$

and

$$\check{FP} = \check{p}_o \check{\mathbf{a}}$$

A scatter plot of the estimate of the criterion

$$\sqrt{\hat{FP}^2 + \hat{FN}^2}$$

versus the true value is shown in Figure 3, and reveals a good level of accuracy.

### Tests

A detailed account of the results is given in the Additional data files, where datasets, data preprocessing, analysis and results are described in enough detail to enable the results to be reproduced.

When testing methods in this field it is difficult to find suitable data for which something is known about the true status of the genes. If one chooses to simulate, then the distributions may not be entirely representative of a real-life situation. If one can find non-proprietary real-life data, then the knowledge as to which genes are truly changed may be uncertain. To provide adequate evidence of good performance it is necessary to provide such evidence under different and reproducible conditions.

In the comparison, *samroc*, *t*-test, Wilcoxon, the Bayesian method in [1], and SAM [2] were competing. By the *t*-test I mean the unequal variance *t*-test:  $t = (\text{mean}_1 - \text{mean}_2) / \sqrt{(s_1^2/n_1 + s_2^2/n_2)}$  for sample means *mean*<sub>1</sub> and *mean*<sub>2</sub> and sample variances *s*<sub>1</sub><sup>2</sup>, *s*<sub>2</sub><sup>2</sup>. The Wilcoxon rank sum test is based on the sum *W*<sub>*s*</sub> of the ranks of the observations in one of the groups  $W_s = R_{1...} + R_{n1}$  [15]. The Bayesian method calculates the posterior odds for genes being changed (available as functions *stat.bay.est.lin* in the R package SAG, and *stat.bayesian* in the R package sma [1,5]). The method starts from the assumption of a joint *a priori* distribution of the effect estimate and the standard error. The former is assumed normal and the latter inverse Gamma.

### Simulated cDNA data

The normal distributions modeled after real-life cDNA data used in Baldi and Long [4] were used here to provide a testing ground for the methods (Table 2). In each simulation two groups of four arrays each were created. Three datasets with 1%, 5% and 10% DEGs were generated using the normal distributions. In all cases *samroc* and the *t*-test coincided (*S*<sub>o</sub> = 0), and were the best methods in terms of the ROC curves. Theory predicts that the *t*-test is optimal in this situation (see Additional data files). When data were antilogarithm-transformed, giving rise to lognormal distributions, *samroc* again came out best, followed by the Bayes method. The *t*-test falls behind this time. Figure 4 gives a graphical presentation of the results in terms of ROC curves.

### Oligonucleotide leukemia data

The data on two types of leukemia, ALL and AML, appeared in Golub *et al.* [16,17]. Samples of both types were hybridized to 38 arrays. In [17], 50 genes were identified as DEGs using statistical analysis of data from the full set of arrays. For these data it is impossible to calculate a ROC curve as the DEGs are unknown. Instead, performance was assessed in terms of the average rank of the 50 genes, after all genes were ranked by their likelihood of being DEGs according to each of the methods. Using just three arrays from each of the two groups, *samroc* gave the best results, followed by SAM (Table 3). This




Figure 4 (see legend on next page)

**Figure 4** (see previous page)

Simulated normal and log-normal data. **(a)** Normal distribution, 1% DEGs. As expected with independent normally distributed observations, the *t*-test will perform quite well, and is matched by *samroc*, which in this case equals the equal-variance *t*-test. The Bayes method has problems with these data, with SAM and Wilcoxon somewhere in between these extremes. **(b)** Lognormal distribution, 1% DEGs. *samroc* may have a slight advantage for shorter lists, whereas the Bayes method is better for longer lists, where the number of false positives is larger. The other three methods lag behind, but not by much. **(c)** Normal distribution, 5% DEGs. The *t*-test and *samroc* coincide; *samroc* is now equivalent to the equal-variance *t*-test, which behaves in the same way as the unequal-variance *t*-test in this case. **(d)** Lognormal distribution, 5% DEGs. The difference between methods is less when data are exponentiated. However, *samroc* has the edge for a wide range of cutoffs, but the Bayes method catches up when more genes are selected. The other three methods are struggling to avoid last spot. **(e)** Normal distribution, 10% DEGs. Again the *samroc* and the *t*-test coincide and the Bayes method has problems with normal data. SAM is also lagging behind, while the other three are very close together. **(f)** Lognormal distribution, 10% DEGs. *samroc* comes out well; Wilcoxon has the worst performance, SAM and the *t*-test are scarcely better, while the Bayes method is intermediate.

means that a necessary but not sufficient condition for the superiority of *samroc* in terms of ROC curves is satisfied (see Additional data files).

*Affymetrix spiking experiment data*

In this test, data generated by Affymetrix in an experiment where 14 transcripts were spiked at known quantities (Table 4) [18,19] were used. Using three arrays from each of two groups of arrays where 14 probe sets (genes) differ, further datasets with 140 and 714 DEGs were generated by a bootstrap procedure. Thus there were three datasets with roughly 0.1%, 1% and 5% DEGs. In two of these three settings *samroc* performed best, and in one case (0.1%) SAM and the Bayes method were better. Figure 5 gives a graphical presentation of these results in terms of ROC curves.

**Discussion**

Whether to look at data on a log scale or not is a tricky question, and is beyond the scope of this article. However, the best performance by the tests considered was achieved when data were lognormal (see Additional data files). Normal, lognormal and real-life data were all included in order to supply a varied testing ground.

As pointed out in [20], the Bayes statistic is for ranking purposes equivalent to a penalized *t*-statistic  $t_p = (\text{mean}_1 -$

$\text{mean}_2)/\sqrt{(a_1 + S^2)}$ . Here  $a_1$  is a scale parameter related to the *a priori* distribution of the standard error. This means that it is, at least in form, closely related to the *t*-test, SAM and *samroc*. SAM, on the other hand, chooses as its fudge constant the value among the percentiles of  $S$ , which minimizes the coefficient of variation of the median absolute deviation of the test statistic computed over a number of percentiles of  $S$  [3]. It is interesting to note how different the three related statistics the Bayes method, SAM and *samroc* turn out in practice.

One clue to why this difference occurs emerges when comparing the denominators of SAM/*samroc* and Bayes more closely. First square the denominators of (1) and the representation of Bayes above. We obtain  $(a + S)^2 = a^2 + 2aS + S^2$  for (1) and  $a_1 + S^2$  for Bayes (where generally  $a_1 \geq a_2$ ). For large values of  $S$  the former will exceed the latter. This means that SAM/*samroc* will downplay the importance of the results for high expressing genes in a way that the Bayes method does not.

But there is also another difference. The Bayes method seems to achieve best when the number of false positives is allowed to grow rather large. The constant  $a$  corresponds to a large percentile in the distribution of the  $S^2$  values (see Additional data files). Whereas the constant in SAM will generally be rather small, often the 5-10% percentile of the  $S$  values, the constant in the Bayes method will correspond to at least the 40% percentile of the  $S^2$  values. It seems that using a large percentile will give a good performance when the number of false positives grows large. This observation is consistent with the observation made in Lonnstedt and Speed [1] that the particular version of SAM, which always uses the 90% percentile, will pass the Bayes method when the number of false positives is allowed to grow large. Also, *samroc* will in general make use of a smaller percentile, albeit that *samroc* shows greater spread between datasets in the values chosen, as a result of its adaptation to the features specific to the data at hand.


*Samroc* is the only method that makes explicit use of the number of changed genes in the ranking. If one has reason to believe, for example from studying expression (3), that there are very few DEGs ( $\ll 1\%$ ), then *samroc* is probably not the first choice. Probably SAM or the Bayes method is more

**Table 2**

**The normal distributions simulated defined by their means and standard deviations**

$Mean_1$	$sd_1$	$Mean_2$	$sd_2$
-8	0.2	-8	0.2
-10	0.4	-10	0.4
-12	1.0	-12	1.0
-6	0.1	-6.1	0.1
-8	0.2	-8.5	0.2
-10	0.4	-11	0.7

The first three rows do not represent differential expression, while the last three rows do.



**Figure 5**

**Figure 5**

Spike data. **(a)** Spike data with 14 DEGs. Three arrays from each group in the Affymetrix spike experiment were used. The granularity of Wilcoxon shows up here as a lack of performance, and at this sample size Wilcoxon is not an option. SAM starts off optimistically, and then falls back when the lists become longer and the false positives more, and *samroc* and Bayes catch up with it. In particular, the latter performs strongly. **(b)** Spike data with 154 DEGs. The spike data with an added 140 changed genes obtained from adding permuted residuals to group means for the 14 spiked genes, generating three arrays per group. This makes the percentage of DEGs just above 1%. We see that *samroc* improves considerably compared to (a), and now shows the best performance for a wide range of top list sizes. **(c)** Spike data with 714 DEGs. The spike data with an added 700 changed genes obtained from adding permuted residuals to group means for the 14 spiked genes, generating three arrays per group. This makes the percentage DEGs just above 5%. Now *samroc* takes the lead, and when the false positives reach roughly 10%, it is passed by the Bayes method. This point corresponds to a top list of roughly 1,400.

useful in these situations. If, on the other hand, the number of DEGs is reasonably large, *samroc* is conjectured to take precedence over SAM, and to be more robust than the Bayes method. Furthermore, one can argue that the kind of experiments undertaken in drug discovery would more often than not end in comparisons in which the biological systems show vast differences in a large number of genes, mostly as a downstream effect of some shock to the system.

The proposed method comes out better than or as good as the original SAM statistic in most tests performed. The *samroc* statistic is robust and flexible in that it can address all sorts of problems that suit a linear model. The methodology adjusts the fudge constant flexibly and achieves an improved performance. The algorithm gives fewer false positives and fewer false negatives in many situations, and was never much worse than the best test statistic in any circumstance. However, a typical run with real-life data will take several hours on a desktop computer. To make this methodology better suited for production it would be a good investment to translate part of the R code, or the whole of it, into C.

To improve on standard univariate tests one must make use of the fact that data are available on a large number of related tests. One way of achieving this goal has been shown in this paper. The conclusion is that it is possible and sensible to calibrate the test with respect to estimates of the false-positive and false-negative rates.

**Additional data files**

A zip file (Additional data file 1) containing the R package SAG for retrieval, preparation and analysis of data from the Affymetrix GeneChip and the R script (Additional data file 2) are available with the online version of this article. An appendix (Additional data file 3) giving further details of the statistical methods and the *samroc* algorithm is also available as a PDF file.

**Table 3**

Ranking based on the leukemia data [16]				
Gene	t-test rank	SAM rank	samroc rank	Bayes rank
M55150	7,052	7,048	6,749.5	5,711
M21551	4,918	4,995	6,203	6,686
M81933	6,204	6,161	5,747	5,094
U63289	5,719	5,731	6,697	6,915
M11147	6,878	6,954	7086	7,087
U41767	6,391	6,557	5,719	4,726
M16038	1,152	1,212	2,232	4,044
U50136	7,055	7,047	7,089	7,026
M13485	6,257	6,237	6,849	6,994
D49950	6,286	6,500	6,671	6,488
M80254	4,303	4,374	5,274	5,807
U51336	6,466	6,554	6,406	5,832
X95735	7,047	7,054	7,112	7,115
M62762	7,094	7,118	6,939	5,820
L08177	7,066	7,119	7,126	7,120
Z30644	1,655	1,720	2,458	3,495
U12471	6,905	6,800	6,096	5,000
M21904	6,136	6,118	6,477	6,428
U05681	5,814	5,725	5,915	5,702
U77604	6,825	7,017	7,105	7,113
D50310	4,507	4,744	5,967	6,534
Z48501	7,008	7,030	7,067	6,941
M81758	6,303	6,331	6,918	7,033
U82759	6,266	6,386	6,106	5,437
M95678	6,836	6,899	7,006	6,908
X74262	7,061	7,085	7,119	7,121
M91432	6,797	6,959	7,050	6,997
HG1612-HT1612	6,733	6,668	6,504	5,883
M31211	6,780	6,813	5,610	4,375
X59417	6,382	6,707	7,008	7,061
Z69881	7,100	7,124	6,860	5,476
U22376	7,068	7,100	7,106	7,007
L07758	7,091	7,114	7,127	7,128
L47738	6,997	6,974	6,944	6,520
U32944	5,485	5,908	6,751	6,953
U26266	6,735	6,966	7,091	7,101
M92287	6,812	6,969	7,070	7,054
U05259	6,987	7,003	7,074	7,029
M65214	6,947	7,058	7,115	7,119
L13278	7,086	7,113	7,120	7,103
M31523	6,963	7,035	6,968	6,454
M77142	6,789	6,929	7,075	7,090
U09087	6,909	6,987	7,021	6,809
D38073	6,698	6,738	6,916	6,815
U38846	6,593	6,827	7,062	7,099
J05243	7,129	7,128	7,096	6,539
D26156	6,962	7,012	7,046	6,874

**Table 3 (Continued)**

Ranking based on the leukemia data [16]				
X15414	6,608	6,790	6,117	5,023
S50223	6809	6,861	6,629	5,886
X74801	6,726	6,895	7,032	6,996
Average	6,367.8	6,443.88	6,550.51	6,371.36

Results for the leukemia data using only the first four samples from ALL and AML. The higher the average rank the better the method has been at identifying the probe sets that are changed.

**Table 4**

Transcript	Experiments	
	M, N, O, P	Q, R, S, T
1	512	1,024
2	1,024	0
3	0	0.25
4	0.25	0.5
5	0.5	1
6	1	2
7	2	4
8	4	8
9	8	16
10	16	32
11	32	64
12	512	1024
13	128	256
14	256	512

The table shows the part of the design of the Affymetrix spike experiment used as a testing ground for methods of ranking genes with respect to differential expression. Out of the 12,626 probe sets on the U95A array 14 transcripts have been spiked at known quantities in picomols selected according to a Latin square design. Here 'experiment' (M, N, O..., T) refers to a set of three arrays with the same spiking. The numbers indicate the amount of spike transcript in pM.

### Acknowledgements

Ingrid Lonnstedt generously made the code to a linear models version of *stat.bay.est* available. Comments from Terry Speed are gratefully acknowledged, among them the suggestion to use spike data and ROC curves in the evaluation, as is the input from Brian Middleton and Witte Koopmann.

### References

- Lonnstedt I, Speed TP: **Replicated microarray data.** *Stat Sinica* 2002, **12**:31-46.
- Tusher VG, Tibshirani R, Chu G: **Significance analysis of microarrays applied to the ionizing radiation response.** *Proc Natl Acad Sci USA* 2001, **98**:5116-5121.
- Chu G, Narasimhan B, Tibshirani R, Tusher VG: **SAM Version 1.12:**



- user's guide and technical document. [http://www-stat.stanford.edu/~tibs/SAM/].
4. Baldi P, Long AD: **A Bayesian framework for the analysis of microarray expression data: regularized t-test and statistical inferences of gene changes.** *Bioinformatics* 2001, **17**:509-519.
  5. **The Comprehensive R Archive Network** [http://www.cran.r-project.org]
  6. Ihaka R, Gentleman R: **R: a language for data analysis and graphics.** *J Comput Graph Stat* 1996, **5**:299-314.
  7. **Supplementary files: SAG and simulation script** [http://home.swipnet.se/pibroberg]
  8. Lovell DR, Dance CR, Niranjani M, Prager RW, Dalton KJ: **Ranking the effect of different features on the classification of discrete valued data.** In *Engineering Applications of Neural Networks*. Kingston on Thames, London; 1996:487-494.
  9. Genovese C, Wasserman L: **Operating characteristics of the FDR procedure.** Technical Report. New York, Carnegie Mellon University 2001.
  10. Dudoit S, Yang YH, Speed TP, Callow MJ: **Statistical methods for identifying differentially expressed genes in replicated cDNA microarray experiments.** *Stat Sinica* 2002, **12**:111-140.
  11. Davison AC, Hinkley DV: *Bootstrap Methods and their Application*. Cambridge, UK: Cambridge University Press; 1997.
  12. Storey JD: **A direct approach to false discovery rates.** Technical Report. Stanford, CA: Stanford University; 2001.
  13. Efron B, Tibshirani R, Storey JD, Tusher VG: **Empirical Bayes analysis of a microarray experiment.** *J Am Stat Assoc* 2001, **96**:1151-1160.
  14. Benjamini Y, Hochberg Y: **Controlling the false discovery rate: a practical and powerful approach to multiple testing.** *J R Stat Soc B* 1995, **57**:963-971.
  15. Lehmann EL: *Nonparametrics: Statistical Methods Based on Ranks*. San Francisco, CA: Holden-Day; 1975.
  16. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, Coller H, Loh ML, Downing JR, Caligiuri MA, et al.: **Molecular classification of cancer: class discovery and class prediction by gene expression monitoring.** *Science* 1999, **286**:531-537.
  17. **Whitehead Institute Center for Genome Research: Cancer Genomics Publications Data Sets** [http://www-genome.wi.mit.edu/cgi-bin/cancer/datasets.cgi]
  18. **Speed Group Microarray Page - Affymetrix data analysis** [http://www.stat.berkeley.edu/users/terry/zarray/Affy]
  19. **Affymetrix** [http://www.affymetrix.com]
  20. Smyth GK, Yang YH, Speed TP: **Statistical issues in cDNA microarray data analysis** [http://www.stat.berkeley.edu/users/terry/zarray/Html/papersindex.html].
  21. **Bioconductor software for bioinformatics** [http://www.bioconductor.org]
  22. Callow MJ, Dudoit S, Gong EL, Speed TP, Rubin EM: **Microarray expression profiling identifies genes with altered expression in hdl-deficient mice.** *Genome Res* 2000, **10**:2022-2029.
  23. Arfin SM, Long AD, Ito T, Tollerli L, Riehle MM, Paegle ES, Hatfield GW: **Global gene expression profiling in Escherichia coli K12: the effect of integration host factor.** *J Biol Chem* 2000, **275**:29672-29684.
  24. Lehmann EL: *Testing Statistical Hypothesis*. New York: Wiley; 1959.
  25. Pan W: **A comparative review of statistical methods for discovering differentially expressed genes in replicated microarray experiments.** *Bioinformatics* 2002, **18**:546-554.
  26. Irizarry RA, Hobbs B, Speed TP: **Exploration, normalization, and summaries of high density oligonucleotide array probe level data** [http://www.stat.berkeley.edu/users/terry/zarray/Affy/GL\_Workshop/genelogic2001.html].
  27. **DNA-Chip Analyzer (dChip)** [http://www.dchip.org]
  28. Li C, Wong WH: **Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection.** *Proc Natl Acad Sci* 2001, **98**:31-36.
  29. Newton MA, Kendziorski CM, Richmond CS, Blattner FR, Tsui KW: **On differential variability of expression ratios: improving statistical inference about gene expression changes from microarray data.** *J Comput Biol* 2001, **8**:37-52.
  30. Tsodikov A, Szabo A, Jones D: **Adjustments and measures of differential expression for microarray data.** *Bioinformatics* 2002, **18**:251-260.
  31. Feller W: *An Introduction to Probability Theory and Its Applications. Volume 2.* 2nd Edition. New York: Wiley; 1971.
  32. **SMAWEHI: An R Library for statistical microarray analysis** [http://bioinf.wehi.edu.au/smawehi/index.html]